Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Culture medium – per se
Reexamination Certificate
2006-11-07
2006-11-07
Lankford, Jr., Leon B. (Department: 1651)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Culture medium, per se
C435S325000, C435S366000, C435S372000, C435S372100, C435S404000, C435S405000, C435S407000
Reexamination Certificate
active
07132288
ABSTRACT:
Disclosed is a medium for cultivating tumor cells, comprising the following constituents, as comprised for example in the medium RPMI 1640: (a) fetal calf serum (FCS), (b) penicillin-streptomycin, (c) L-glutamine, (d) transferrin, (e) insulin, (f) human epidermal growth factor (EGF) and (g) α-TGF. A method for characterizing tumor cells or potential tumor cells, respectively, is also described. Said method includes the culturing of cells in the inventive medium and the two tumor cell lines LNHOS1 and PTHOS1 established by means of the inventive culturing method.
REFERENCES:
patent: 6156516 (2000-12-01), Nunokawa
Hombauer, H., et al., “Selective Interactions Between Epithelial Tumour Cells and Bone Marrow Mesenchymal Stem Cells”; British Journal of Cancer (2000); 82 (7); 1290-1296.
Pantel, K., et al., “Establishment of Micromestastic Carcinoma Cell Lines: A Novel Source of Tumor Cell Vaccines”; Journal of the National Cancer Institute; vol. 87; No. 15, Aug. 2, 1995.
Hosch, S., et al., “Malignant Potential and Cytogenic Characteristics of Occult Disseminated Tumor Cells in Esophegeal Cancer”; Advances in Brief; pp. 6830-6840.
Kurec, A., et al., “Use of the APAAP Method in the Classification and Diagnosis of Hemotologic Disorders”; Clinics in Laboratory Medicine; vol. 7, No. 4 (1988) 223-236.
Gilles, et al., “The Epithelial to Mesenchymal Transition and Metastatic Progression in Carcinoma”, The Breast Journal, vol. 2, No. 1, pp. 83-96, (1996).
Telenius, et al., “Cytogenic Analysis by Chromosome Painting Using DOP-PCR Amplified Flow-Sorted Chromosomes”, Genes, Chromosomes & Cancer, vol. 4, pp. 257-263 (1992).
Byrne, J., et al., “The use of monoclonal antibodies for the histopathological detection of mammary axillary micrometastases.” European Journal of Surgical Oncology, 1987, vol. 13, pp. 409-411.
Calaluce, Robert, et al. “Micrometastasis in Colorectal Carcinoma: A Review.” 1998, vol. 67, pp. 194-202.
Latza, U., et al. “Ber-EP4: new monoclonal antibody which distinguishes epithalia from mesothelia.” 1990, Journal of Clinical Pathology, 1990, vol. 43, pp. 213-219.
Liefers, Gerrit-Jan, et al. “Micrometastases and Survival in Stage II Colorectal Cancer.” New England Journal of Medicine, 1998, vol. 339, pp. 223-228.
Pantel, K., et al.Minimal Residual Epithelial Cancer: Diagnostic Approaches and Prognostic Relevance. Gustav Fischer Verlag Publishing: Stuttgart. 1996.
Passlick, Bernward, et al. “Immunohistochemical Assessment of Individual Tumor Cells in Lymph Nodes of Patients With Non-Small-Cell Lung Cancer.” Journal of Clinical Oncology, vol. 12, pp. 1827-1832.
Raymond, Wendy A., et al. “Immunoperoxidase Staining in the Detection of Lymph Node Metastases in Stage 1 Breast Cancer.” Pathology, 1989, vol. 21, pp. 11-15.
Sidransky, David. “Nucleic Acid-Based Methods for the Detection of Cancer.” Science, 1997, vol. 278, 1054-1058.
Hosch, Stefan B. “Early Lymphatic Tumor Cell Dissemination in Pancreatic Cancer: Frequency and Prognostic Significance.” Pancreas, 1997, vol. 15, pp. 154-159.
Greenson, Joel K., et al. “Identification of Occult Micrometastases in Pericolic Lymph Nodes of Dukes' B Colorectal Cancer Patients Using Monoclonal Antibodies against Cytokeratin and CC49.” CANCER, 1994, vol. 73, pp. 563-569.
Passlick, Berward, et al. “Detection of Disseminated Lung Cancer Cells in Lymph Nodes: Impact on Staging and Prognosis.” Ann. Thorac. Surg., 1996, vol. 61, pp. 177-183.
Nevinny-Stickel, C., et al. “Nonradioactive HLA Class II Typing Using Polymerase Chain Reaction and Digoxigenin-11-2′-3′-dideoxy-uridinetriphosphate-Labeled Oligonucleotide Probes.” Human Immunology, 1991, vol. 31, pp. 7-13.
Speicher, Michael R., et al. “Karyotyping human chromosomes by combinatorial multi-fluor FISH.” Nature Genetics, 1996, vol. 12, pp. 368-375.
Eils, R., et al. “An optimized, fully automated system for fast and accurate identification of chromosomal rearrangements by multiplex-FISH (M-FISH).” Cytogenet Cell Genet, 1998, vol. 82, pp. 160-171.
Lengauer, Christoph, et al. “Metaphase and Interphase Cytogenetics with Alu-PCR-amplified Yeast Artificial Chromosome Clones Containing theBCRGene and the Protooncogenes c-raf-1, c-fms, and c-erbB2.”Cancer Research, 1992, vol. 52, pp. 2590-2596.
Harris, Curtis C. “Structure and Function of the p53 Tumor Suppressor Gene: Clues for Rational Cancer Therapeutic Strategies.” Journal of the National Cancer Institute, 1996, vol. 88, pp. 1442-1455.
Izbicki, Jakob Robert, et al. “Prognostic Value of Immunohistochemically Identifiable Tumor Cells in Lymph Nodes of Patients with Completely Resected Esophageal Cancer.” New England Journal of Medicine, 1997, vol. 337, pp. 1188-1194.
Hosch Stefan
Izbicki Jakob
Scheunemann Peter
Hultquist Steven J.
Intellectual Property / Technology Law
Lankford , Jr. Leon B.
Uni-Klinikum Hamburg-Eppendorf
LandOfFree
Medium for culturing tumor cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medium for culturing tumor cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medium for culturing tumor cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3699775